Twice-daily insulin degludec/insulin aspart effectively improved morning and evening glucose levels and quality of life in patients previously treated with premixed insulin: an observational study

• Published in: Diabetology and metabolic syndrome Vol. 10; no. 1; p. 64
• Main Authors: Fujimoto, Kanta, Iwakura, Toshio, Aburaya, Megumi, Matsuoka, Naoki
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.08.2018; BioMed Central; BMC
• Subjects: Analysis; Blood glucose; Care and treatment; Clinical trials; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetic retinopathy; Diabetics; Fasting; Glucose; Glucose monitoring; Glucose variability; Hypoglycemia; Insulin; Insulin degludec/insulin aspart; Laboratory testing; Observational studies; Patients; Psychological assessment; Quality of life; Type 2 diabetes; Type 2 diabetes; Insulin degludec/insulin aspart; Glucose variability; Quality of life
• ISSN: 1758-5996; 1758-5996
• DOI: 10.1186/s13098-018-0366-x

Previous studies comparing insulin degludec/insulin aspart (IDegAsp) with premixed insulin twice daily among insulin users with type 2 diabetes have not thoroughly investigated differences in the glucose variability and psychological evaluations related to insulin regimen changes. We investigated changes in the daily and day-to-day glucose variability and quality of life (QOL) related to insulin use in patients with type 2 diabetes during a switch from premixed insulin preparations comprising either human insulin (BHI30) or insulin aspart (BIAsp30) to IDegAsp twice daily. In this prospective observational study, 22 subjects (BHI30:BIAsp30 = 12:10) self-measured their blood glucose levels every morning, and before and after all meals each week. Premixed insulin was administered for the first 2 months, followed by IDegAsp for the next 2 months. Efficacy measures were evaluated during the last month or last day of both phases. The mean blood glucose levels (175.5 vs. 163.0 mg/dL; = 0.004) and the M-values (53.9 vs. 27.6; = 0.049) were significantly lower in the IDegAsp phase. However, no differences in the standard deviations of morning fasting glucose levels were observed between phases (premixed vs. IDegAsp, 20.0 vs. 19.3 mg/dL; = 0.343). Compared to the premixed phase, the before-breakfast (145.3 vs. 126.0 mg/dL; < 0.001), after-breakfast (190.3 vs. 170.7 mg/dL; = 0.001), before-dinner (153.0 vs. 140.1 mg/dL;  = 0.007), and after-dinner glucose levels (198.7 vs. 181.4 mg/dL; = 0.018) were lower in the IDegAsp phase. However, the before-lunch (150.8 vs. 148.2 mg/dL; = 0.329) and after-lunch glucose levels (214.7 vs. 211.4 mg/dL; = 0.308) did not significantly differ between phases. Regarding QOL, the total and therapy-related feeling Insulin Therapy Related-QOL (ITR-QOL) questionnaire scores favored IDegAsp, as did the ITR-QOL at Night questionnaire subscale score of glycemic control before breakfast. Although the day-to-day variability of morning fasting glucose levels did not change, switching to IDegAsp improved daily glucose level variability, the morning and evening glucose control and QOL among patients treated with premixed insulin. University Hospital Medical Information Network Clinical Trials Registry, UMIN000021939. Prospectively registered 18 April 2016.